微创医疗（00853.HK）今日盘中股价大涨5.95%，引发市场广泛关注。这一显著涨幅与公司近期发布的重要研究成果密切相关。
据悉，微创医疗自主研发的Firehawk®/火鹰®冠脉雷帕霉素药物靶向洗脱支架系统的欧洲TARGET-FIRST临床研究结果近日在《新英格兰医学杂志》（NEJM）全文刊登，并在欧洲心脏病学2025年会（ESC 2025）上作为"最新突破性临床试验"发布。研究结果显示，对于植入Firehawk®/火鹰®支架的低风险急性心肌梗死患者，双联抗血小板治疗（DAPT）疗程可从12个月缩短至1个月，不仅没有增加缺血风险，还可大幅降低出血并发症达54%。
这一研究成果在全球顶级医学期刊和心血管学术会议同步发表，凸显了Firehawk®/火鹰®支架的独特临床价值。目前，该支架已进入全球67个国家和地区。业内专家认为，这一突破性成果有望改变全球临床实践，并为微创医疗在国际市场的拓展带来新的机遇，这可能是推动公司股价大幅上涨的主要原因。投资者对公司未来发展前景的信心明显增强，尤其是在北美等高端市场的商业化潜力方面。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.